Antibody responses post-booster COVID-19 vaccination: Insights from a single-center prospective cohort study

The study aimed to evaluate the effect of booster dose COVID-19 vaccines on prevention and humoral immune response in individuals with different vaccination schemes during the period BA.4 and BA.5 omicron sub-variants were globally dominant. The study included 146 individuals who preferred different...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostic microbiology and infectious disease 2024-10, Vol.110 (2), p.116425, Article 116425
Main Authors: Dinç, Harika-Öykü, Can, Günay, Budak, Beyhan, Daşdemir, Ferhat-Osman, Keskin, Elif, Kirkoyun-Uysal, Hayriye, Aydoğan, Okan, Balkan, Ilker-Inanç, Karaali, Rıdvan, Ergin, Sevgi, Saltoğlu, Neşe, Kocazeybek, Bekir
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antibody
Antibody Formation - immunology
BNT162 Vaccine - administration & dosage
BNT162 Vaccine - immunology
BNT162b2
CoronaVac
COVID-19
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - immunology
Female
Humans
Immunization, Secondary
Immunoglobulin G - blood
Male
Middle Aged
Omicron
Prospective Studies
SARS-CoV-2 - immunology
Spike Glycoprotein, Coronavirus - immunology
Vaccination
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study aimed to evaluate the effect of booster dose COVID-19 vaccines on prevention and humoral immune response in individuals with different vaccination schemes during the period BA.4 and BA.5 omicron sub-variants were globally dominant. The study included 146 individuals who preferred different vaccination schemes for booster doses. Anti-spike/RBD-IgG and neutralizing antibody levels were measured 28 days after the booster dose vaccination upon their consent. There is no significant difference between median antibody titers detected according to different vaccination schemes. SARS-CoV-2 neutralizing antibody inhibition percentages were detected significantly higher in serum samples before and after the last booster dose in 2 BNT162b2+1 BNT162b2(99.42 %), 2 BNT162b2 + 2 BNT162b2(99.42 %), and 2 BNT162b2 + 3 BNT162b2(99.42 %) vaccination schemes (p = 0.004, p = 0.044, p = 0.002,respectively). The study indicated that a booster vaccination dose provides a high level of protection against severe COVID-19 and death. We think that the variant-specific pancoronavirus vaccines will be necessary to protect against breakthrough infections.
ISSN:0732-8893
1879-0070
1879-0070
DOI:10.1016/j.diagmicrobio.2024.116425